|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings link the distorted expression of SMURF2 to human carcinogenesis and suggest the alterations in SMURF2 localization as a potential mechanism obliterating its tumor suppressor activities.
|
31003445 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>MIR503HG</i>-induced proliferation was mediated by the induction of <i>microRNA-503</i> (<i>miR</i>-<i>503</i>) and suppression of Smurf2, resulting in stabilization of the tumor growth factor-β receptor (TGFBR) and enhanced tumor cell growth.
|
29758012 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also highlight the studies demonstrating the impact of Smurf proteins on tumor cell sensitivity to anticancer therapies.
|
30116722 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By means of a tool-box of fluorescent antibodies, green fluorescent protein (GFP) tagging, or specific oligonucleotides, we present tumor relevant re-arrangements of Erb-receptors in membranes, spatial organization of Smad specific ubiquitin protein ligase 2 (Smurf2) in the cytosol, tumor cell characteristic heterochromatin organization, and molecular re-arrangements induced by radiation or antibody treatment.
|
28956810 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All Smurf2-deficient mice develop visible DLBCL tumor starting at 15 months of age.
|
28107482 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results identified Smurf2 as an essential regulator of Topo IIα, providing novel insights into its control and into the suggested tumor-suppressor functions of Smurf2.<i></i>.
|
28611047 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, invasive ductal carcinomas showed focal or diffuse decrease in Smurf2 expression, which was observed more frequently in triple-negative tumors than in ER-positive tumors.
|
24485087 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a proof of principle, we demonstrate that Smurf2 silencing reduces the clonogenic survival in vitro and prolongs tumor latency in vivo in cancer cells including mutant KRAS-driven tumors.
|
24709419 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that SMURF2-mediated protective ubiquitination of EGFR may be responsible for EGFR overexpression in certain tumors and support targeting SMURF2-EGFR interaction as a novel therapeutic approach in treating EGFR-addicted tumors.
|
21750651 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcription of the E3 ubiquitin ligase SMURF2 was significantly higher in organ-confined tumours (pT2) compared with non-organ-confined cancers (pT3).
|
21102547 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results, which reveal a previously unsuspected tumor suppression function for Smurf2-induced senescence, suggest that modulation of Smurf2 action may be a useful strategy for inhibition of cancer cell growth.
|
18181147 |
2008 |